Extending the drug discovery pipeline to simultaneously-applied chemical agents, and extending the study of evolution to simultaneous mutations, through an ab initio model that relates changes in phenotype to changes in molecular binding interactions

Furuhashi, 2008, Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets, Nat Rev Drug Discov, 7, 489, 10.1038/nrd2589 Clerc, 2016, Nonlinear effects in evolution – an ab initio study: a model in which the classical theory of evolution occurs as a special case, J Theor Biol, 40, 94, 10.1016/j.jtbi.2016.03.026 Buller, 2001, Molecular effects of Eya1 domain mutations causing organ defects in BOR syndrome, Hum Mol Genet, 10, 2775, 10.1093/hmg/10.24.2775 Landgraf, 2010, Sipl1 and Rbck1 are novel Eya1-binding proteins with a role in craniofacial development, Mol Cell Biol, 30, 5764, 10.1128/MCB.01645-09 Cade, 2010, Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities, Protein Sci, 19, 458, 10.1002/pro.324 Comas, 2012, Whole-genome sequencing of rifampicin-resistant M. tuberculosis strains identifies compensatory mutations in RNA polymerase, Nat Genet, 44, 106, 10.1038/ng.1038 Zhang, 2003, Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid, J Antimicrob Chemother, 52, 790, 10.1093/jac/dkg446 Sliwoski, 2014, Assoc. Editor, Computational methods in drug discovery, Pharmacol Rev, 66, 334, 10.1124/pr.112.007336 Lee, 2017, Structure-based understanding of binding affinity and mode of estrogen receptor α agonists and antagonists, PLoS One, 12, 10.1371/journal.pone.0169607